BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Abdul-Baki H, El Hajj II, ElZahabi L, Azar C, Aoun E, Skoury A, Chaar H, Sharara AI. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol 2009; 15(29): 3636-3642 [PMID: 19653341 DOI: 10.3748/wjg.15.3636]
URL: https://www.wjgnet.com/1007-9327/full/v15/i29/3636.htm
Number Citing Articles
1
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndromeExpert Opinion on Drug Metabolism & Toxicology 2020; 16(7): 583 doi: 10.1080/17425255.2020.1767067
2
Peter Layer. Handbuch Gastroenterologie 20102010; : 303 doi: 10.1007/978-3-642-11635-3_9
3
Anita Sainsbury, Alexander C. Ford. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agentsTherapeutic Advances in Gastroenterology 2011; 4(2): 115 doi: 10.1177/1756283X10387203
4
Johanne L Agger, Andreas Schröder, Lise K Gormsen, Jens S Jensen, Troels S Jensen, Per K Fink. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised studyThe Lancet Psychiatry 2017; 4(5): 378 doi: 10.1016/S2215-0366(17)30126-8
5
A. C. Ford, P. Moayyedi. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndromeAlimentary Pharmacology & Therapeutics 2010; 32(2): 144 doi: 10.1111/j.1365-2036.2010.04328.x
6
Chen Xie, Yurong Tang, Yunfeng Wang, Ting Yu, Yun Wang, Liuqin Jiang, Lin Lin, Lin Lu. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-AnalysisPLOS ONE 2015; 10(8): e0127815 doi: 10.1371/journal.pone.0127815
7
Michelle Bosman, Sigrid Elsenbruch, Maura Corsetti, Jan Tack, Magnus Simrén, Bjorn Winkens, Thimo Boumans, Ad Masclee, Daniel Keszthelyi. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology 2021; 6(6): 459 doi: 10.1016/S2468-1253(21)00023-6
8
Alexander C. Ford, Brian E. Lacy, Lucinda A. Harris, Eamonn M.M. Quigley, Paul Moayyedi. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology 2019; 114(1): 21 doi: 10.1038/s41395-018-0222-5
9
H. Duboc, M. Dior, B. Coffin. Le syndrome de l’intestin irritable : nouvelles pistes physiopathologiques et conséquences pratiquesLa Revue de Médecine Interne 2016; 37(8): 536 doi: 10.1016/j.revmed.2015.12.030
10
Agnieszka Kułak-Bejda, Grzegorz Bejda, Napoleon Waszkiewicz. Antidepressants for irritable bowel syndrome—A systematic reviewPharmacological Reports 2017; 69(6): 1366 doi: 10.1016/j.pharep.2017.05.014
11
Alexander C. Ford, Paul Moayyedi, William D. Chey, Lucinda A. Harris, Brian E. Lacy, Yuri A. Saito, Eamonn M. M. Quigley. American College of Gastroenterology Monograph on Management of Irritable Bowel SyndromeAmerican Journal of Gastroenterology 2018; 113: 1 doi: 10.1038/s41395-018-0084-x
12
Christopher J Black, Yuhong Yuan, Christian P Selinger, Michael Camilleri, Eamonn M M Quigley, Paul Moayyedi, Alexander C Ford. Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysisThe Lancet Gastroenterology & Hepatology 2020; 5(2): 117 doi: 10.1016/S2468-1253(19)30324-3
13
Ola Ghaith, Mustapha El-Halabi, Jana G Hashash, Ala I Sharara. Investigational agents for the irritable bowel syndromeExpert Opinion on Investigational Drugs 2010; 19(10): 1161 doi: 10.1517/13543784.2010.513380
14
Reham Gendi, Nusrat Jahan. Pharmacological and Non-pharmacological Treatments of Irritable Bowel Syndrome and Their Impact on the Quality of Life: A Literature ReviewCureus 2020;  doi: 10.7759/cureus.9324
15
T Mazzawi, T Hausken, D Gundersen, M El-Salhy. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndromeEuropean Journal of Clinical Nutrition 2015; 69(4): 519 doi: 10.1038/ejcn.2014.151
16
Tarek Mazzawi, Doris Gundersen, Trygve Hausken, Magdy El-Salhy. Increased Chromogranin A Cell Density in the Large Intestine of Patients with Irritable Bowel Syndrome after Receiving Dietary GuidanceGastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/823897
17
Ruben D Acosta, Brooks D Cash. Existing and emerging therapies for irritable bowel syndromeExpert Opinion on Emerging Drugs 2011; 16(2): 389 doi: 10.1517/14728214.2011.566214
18
Emanuele Sinagra, Claudia Romano, Mario Cottone. Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel SyndromeGastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/486067
19
Sun Jung Oh, Will Takakura, Ali Rezaie. Shortcomings of Trials Assessing Antidepressants in the Management of Irritable Bowel Syndrome: A Critical ReviewJournal of Clinical Medicine 2020; 9(9): 2933 doi: 10.3390/jcm9092933
20
Tarek Mazzawi, Magdy El-Salhy. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidanceExperimental Biology and Medicine 2017; 242(13): 1355 doi: 10.1177/1535370217699537
21
Lisa Ruepert, A Otto Quartero, Niek J de Wit, Geert J van der Heijden, Gregory Rubin, Jean WM Muris. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndromeCochrane Database of Systematic Reviews 2011; 2013(3) doi: 10.1002/14651858.CD003460.pub3
22
Magdy El-Salhy. Recent advances in the diagnosis of irritable bowel syndromeExpert Review of Gastroenterology & Hepatology 2015; 9(9): 1161 doi: 10.1586/17474124.2015.1067138
23
Esther Colomier, Joost Algera, Chloé Melchior. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With DiarrheaFrontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.629026
24
Tarek Mazzawi, Magdy El-Salhy. Dietary guidance and ileal enteroendocrine cells in patients with irritable bowel syndromeExperimental and Therapeutic Medicine 2016; 12(3): 1398 doi: 10.3892/etm.2016.3491
25
Alexander C Ford, Paul Moayyedi, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel, Eamonn M M Quigley. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationAmerican Journal of Gastroenterology 2014; 109: S2 doi: 10.1038/ajg.2014.187
26
H.P. Kapfhammer. Psychopharmakotherapeutische Ansätze bei somatoformen Störungen und funktionellen KörpersyndromenDer Nervenarzt 2012; 83(9): 1128 doi: 10.1007/s00115-011-3446-9
27
Yingcong Yu, Shujuan Wu, Jianxin Li, Renye Wang, Xupei Xie, Xuefeng Yu, Jianchun Pan, Ying Xu, Liang Zheng. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signalingMetabolic Brain Disease 2015; 30(1): 47 doi: 10.1007/s11011-014-9554-z
28
Nana Xiong, Yanping Duan, Jing Wei, Ricarda Mewes, Rainer Leonhart. Antidepressants vs. Placebo for the Treatment of Functional Gastrointestinal Disorders in Adults: A Systematic Review and Meta-AnalysisFrontiers in Psychiatry 2018; 9 doi: 10.3389/fpsyt.2018.00659
29
Judy Nee, Mohammed Zakari, Anthony J Lembo. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndromeExpert Opinion on Pharmacotherapy 2015; 16(18): 2781 doi: 10.1517/14656566.2015.1101449
30
Madhusudan Grover, Douglas A. Drossman. Centrally Acting Therapies for Irritable Bowel SyndromeGastroenterology Clinics of North America 2011; 40(1): 183 doi: 10.1016/j.gtc.2010.12.003
31
Alexander C Ford, Eamonn M M Quigley, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel, Paul Moayyedi. Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology 2014; 109(9): 1350 doi: 10.1038/ajg.2014.148
32
Yuanjun Dong, David Baumeister, Sabrina Berens, Wolfgang Eich, Jonas Tesarz. High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary CareFrontiers in Psychiatry 2019; 10 doi: 10.3389/fpsyt.2019.00714
33
TAREK MAZZAWI, MAGDY EL-SALHY. Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidanceInternational Journal of Molecular Medicine 2016; 37(5): 1247 doi: 10.3892/ijmm.2016.2523
34
T Mazzawi, T Hausken, D Gundersen, M El-Salhy. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndromeEuropean Journal of Clinical Nutrition 2016; 70(2): 175 doi: 10.1038/ejcn.2015.191
35
Brian E. Lacy, Mark Pimentel, Darren M. Brenner, William D. Chey, Laurie A. Keefer, Millie D. Long, Baha Moshiree. ACG Clinical Guideline: Management of Irritable Bowel SyndromeAmerican Journal of Gastroenterology 2021; 116(1): 17 doi: 10.14309/ajg.0000000000001036
36
Robyn Rexwinkel, Judith Zeevenhooven, Faridi S. van Etten-Jamaludin, Marc A. Benninga, Merit M. Tabbers. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic reviewExpert Opinion on Drug Safety 2019; 18(2): 111 doi: 10.1080/14740338.2019.1574295